| 摘要 |
<p>The present invention relates to oligomer compounds (oligomers), which target APO- B100 mRNA in a cell, leading to reduced expression of APO-B100. Reduction of APO-B100 expression is beneficial for the treatment of certain medical disorders, such as diseases associated with apolipoproteinB activity, such as in non-limiting example, different types of HDL/LDL cholesterol imbalance; dyslipidemias, e.g., familial combined hyperlipidemia (FCHL), acquired hyperlipidemia, hypercholesterolemia, statin-resistant hypercholesterolemia; coronary artery disease (CAD), coronary heart disease (CHD), atherosclerosis.</p> |
| 申请人 |
SANTARIS PHARMA A/S;NIELSEN, NIELS FISKER;STRAARUP, ELLEN MARIE;LINDHOLM, MARIE |
发明人 |
NIELSEN, NIELS FISKER;STRAARUP, ELLEN MARIE;LINDHOLM, MARIE |
